维持高血红蛋白水平对肾移植受者长期肾功能的影响:一项随机对照试验
这项开放标签、多中心随机对照试验对肾移植受者随访3年,比较维持高血红蛋白(12.5-13.5 g/dL)与低血红蛋白(10.5-11.5 g/dL)对移植肾功能下降速率的影响。结果显示低血红蛋白组eGFR下降幅度显著大于高血红蛋白组(-5.1 ± 9.5 vs -1.0 ± 8.4 mL/min/1.73 m2,P = 0.02)。结论提示纠正贫血至高目标范围可能减缓移植肾慢性期肾功能恶化。
要点
- 高血红蛋白组eGFR下降速率显著低于低血红蛋白组(P = 0.02)。
- 高血红蛋白组仅少数发生心血管事件并回归血透,低血红蛋白组无此类事件。
- 研究期间两组平均血压控制良好。
核心结论
- 纠正贫血至目标血红蛋白范围(12.5-13.5 g/dL)可减缓移植肾慢性期超过3年的肾功能恶化。
研究设计与样本
- 开放标签、多中心、随机对照试验的3年随访,纳入肾移植受者,高血红蛋白组n=64,低血红蛋白组n=63。
主要发现
- 高血红蛋白组平均血红蛋白在3个月时升至>12 g/dL,18个月达到目标范围;36个月时高血红蛋白组平均12.8 ± 0.7 g/dL,低血红蛋白组11.5 ± 1.2 g/dL。
- 低血红蛋白组eGFR下降速率显著大于高血红蛋白组(ΔeGFR -5.1 ± 9.5 vs -1.0 ± 8.4 mL/min/1.73 m2,P = 0.02)。
- 高血红蛋白组仅少数患者发生心血管事件并回归血透,低血红蛋白组无此类事件。
临床怎么用
- 肾移植受者慢性期可考虑将血红蛋白维持在12.5-13.5 g/dL以减缓肾功能下降,但需监测心血管事件。
局限性
- 开放标签设计,样本量较小(高血红蛋白组64例,低血红蛋白组63例),可能影响结果外推。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Posttransplant anemia may be a major determinant of chronic allograft nephropathy. However, the impact of correcting anemia on graft function remains controversial. METHODS: A 3-year follow-up of an open-label, multicenter, randomized controlled trial involving kidney transplantation recipients examined whether sustained maintenance of target hemoglobin (Hb) concentrations at a high level (12.5-13.5 g/dL, n = 64) with either darbepoetin alfa or epoetin beta pegol would slow the graft function decline rate as the primary efficacy endpoint, compared with maintenance of a low Hb concentration (10.5-11.5 g/dL, n = 63). RESULTS: The mean blood pressures in the two groups were well controlled throughout the study. In the high Hb group, mean Hb concentrations increased to >12 g/dL at 3 months, reaching the target range at 18 months. At the end of this study (36 months), the mean Hb concentration was 12.8 ± 0.7 g/dL in the high Hb group and 11.5 ± 1.2 g/dL in the low Hb group. The decline rate of the estimated glomerular filtration (eGFR) rate was considerably greater in the low Hb group (ΔeGFR, -5.1 ± 9.5 mL/min/1.73 m2) than in the high Hb group (-1.0 ± 8.4 mL/min/1.73 m2) (P = 0.02). Of note, only a few high Hb patients developed cardiovascular events and returned to hemodialysis, but the low Hb patients did not. CONCLUSION: This prospective study suggests that correcting anemia to the target Hb level range (12.5-13.5 g/dL) slows renal function deterioration by >3 years in the chronic phase of allograft nephropathy.
引用
- Tsujita M, Kosugi T, Goto N, et al. The effect of maintaining high hemoglobin levels on long-term kidney function in kidney transplant recipients: a randomized controlled trial. Nephrol Dial Transplant. 2019. PMID: 30561729. doi:10.1093/ndt/gfy365
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。